去氧孕烯炔雌醇口服对原发性痛经的有效性及安全性探究

Analysis of the efficacy and safety of oral contraceptives marvelon on patients with primary dysmenorrhea

目的:探究去氧孕烯炔雌醇口服对原发性痛经的有效性与安全性。方法:选择2012年9月至2013年9月我院原发性痛经患者98例,将所选患者随机分为A、B两组,每组49例。A组口服去氧孕烯炔雌醇治疗;B组口服安慰剂治疗,每组治疗3个周期。观察并比较两组治疗效果。结果:A组治疗总有效率为91.84%(45/49);B组治疗总有效率为77.55%(48/49),A组显著高于B组,差异有统计学意义(χ2=3.857,P<0.05)。治疗前A、B两组患者的TDS得分无统计学差异(P>0.05);治疗后A组患者的TDS得分为(1.1±0.5)分,明显低于B组的(2.8±0.7)分,两组比较差异有统计学意义(t=13.755,P<0.01)。治疗后A、B两组患者出现恶心呕吐、乳房胀痛、经量减少等不良反应的比例分别为24.49%(12/49)和20.41%(10/49),两组差异无统计学意义(χ2=0.049,P>0.05)。结论:去氧孕烯炔雌醇口服可有效治疗原发性痛经,可有效缓解患者疼痛,治疗比较安全,值得临床推广应用。

Objectives： To analyze the efficacy and safety of oral contraceptives Marvelon on patients with primary dysmenorrhea. Methods： 98 patients with primary dysmenorrheal treated in our hospital from September 2012 to September 2013 were selected and divided into group A and B randomly, with 49 patients in each group. Group A was given contraceptives Marvelon for treatment and group B was given placebo for treatment, 3 courses foreach group. The effects of the two groups were observed and compared. Results ： The total efficiency rate of group A was 91.84 % （45/49）, which was higher than group B （77.55%, 48/49）, with statistically significant difference （ x^2 = 3. 857, P 〈 0. 05 ）. Difference in the scores of TDS in group A and B were not statistically significant （ P 〉 0. 05 ） before treatment. The TDS scores of group A was （ 1.1 ± 0. 5 ）, lower than （ 2.8 ± 0. 7） in group B and the difference was statistically significant （ t = 13. 755, P 〈0. 01 ） after treatment. The adverse reactions rate of nause- a, vomiting, breast tenderness, menstruation decrease and so on in group A and B were 24.49% （12/49） and 20. 41% （ 10/49）, without statistically significant difference （ P 〉 0. 05 ）. Conclusion： Oral contraceptives Marve- Ion is efficient and safe in treating patients with primary dysmenorrhea, which can effectively relieve pain of patients and is worthy of clinical application.